RankAlpha logo
Back to Rankings

KPTI

Karyopharm TherapeuticsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
View Chart
Current thesis
The constructive read is that KPTI still has two meaningful 2026 shots on goal: more detailed SENTRY data at ASCO on June 2, 2026 and the mid-2026 XPORT-EC-042 readout, while the March financing bought enough time to reach those milestones [#PR-2026-04-21] [#8-K-2026-03-27].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +22.2.
What can break
Liquidity guidance still points only into late Q3 2026 even after the March financing, keeping dilution, debt amendment, partnering or other capital actions in play [#8-K-2026-03-27].
Momentum
54
Value
41
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $14.50 · Bear $4.50
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-03 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $15.00
Why
Momentum54 · Δ7d +18.8
Value41 · Δ7d -0.0
Sentiment63 · Δ7d +22.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
54
26% active weight
Current posture
7d trendSoftening
Δ7d
+18.8
Δ21d
-0.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
63
34% active weight
Current posture
7d trendImproving
Δ7d
+22.2
Δ21d
+18.7
Why this grade

Composite grade C. Momentum 54.3 / Value 41.1 / Sentiment 62.9

Fundamentals (TTM)
As of 2026-07-21
Market Cap
$178.24M
Beta
0.21
Shares Out
22.66M
P/E (TTM) · Derived
-0.4
P/S (TTM)
0.89
P/FCF (TTM) · Derived
-1.78
Rev YoY
+16.8%
EPS YoY
-55.4%
Gross Margin
+95.9%
Op Margin
-73.1%
Net Debt
$169.86M
Current Ratio
1.08
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology